FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

Inclusion Criteria: * \- Histologically proven colorectal adenocarcinoma without RAS mutation * Confirmed, non-resectable metastatic disease (Stage IV) * No prior chemotherapy except perioperative or adjuvant chemotherapy discontinued for more than 12 months * At least one measurable metastasis according to the RECIST v1.1 criteria * Age ≥ 18 years * WHO ≤ 2 * Neutrophils \> 1500 /mm3, platelets\> 100 000/mm3, Hb \> 9 g/dL * Creatinine clearance \> 50 mL/min according to the MDRD formula * Serum bilirubin \< 25 µmol/L, AST, ALT, Alk Phos \< 2.5 x ULN or \< 5 x ULN in case of liver metastases * PT \> 60%, albumin ≥ 25g/L * Estimated life expectancy ≥ 3 months * Patient affiliated to a social security scheme * Patient informed and informed consent form signed Exclusion Criteria: * \- Presence of uncontrolled symptomatic brain metastases * RAS mutation (KRAS or NRAS mutation) * Patient taking warfarin. If treated with anticoagulant at the indicated effective dose, this must be replaced with low molecular weight heparin before inclusion * Known DPD deficiency * Peripheral neuropathy \> 1 (NCI CTCAE v4.0) * Patient with interstitial pneumonitis or pulmonary fibrosis * History of chronic diarrhoea or inflammatory disease of the colon or rectum, or obstruction or sub-obstruction during symptomatic treatment * Poorly controlled chronic skin disease * Any known specific contraindication or allergy to the medicinal products used in the study * Patient simultaneously included in anot…